Key result
99mTc-PYP SPECT reveals ~4x higher SUVmax in ATTR cardiomyopathy versus AL amyloidosis.
Why the study?
This study was aimed to assess the diagnostic feasibility and operator reproducibility of 99mTc-PYP quantitative SPECT in patients with suspected ATTR-CM.
Does 99mTc-PYP quantitative SPECT with partial volume correction accurately differentiate ATTR-CM from other cardiac amyloidosis types and demonstrate operator reproducibility?
Population
Thirty-seven consecutive patients undergoing 99mTc-PYP imaging for suspected ATTR-CM
Comparison
SUVmax across ATTR-CM, AL cardiac amyloidosis, and other pathogens, and across Perugini visual scores
Design
Consecutive observational diagnostic feasibility and reproducibility study
Authors
Loading...
Supports quantitative SPECT differentiation of ATTR-CM; hypothesis-generating and should not yet change practice.
Observational (n=37)
No
Does 99mTc-PYP quantitative SPECT with partial volume correction accurately differentiate ATTR-CM from other cardiac amyloidosis types and demonstrate operator reproducibility?
Absolute Event Rate: 7.5% vs 1.96%
p-value: p=<0.05
99mTc-PYP quantitative SPECT with adjustable partial volume correction is a feasible and highly reproducible method to objectively assess cardiac amyloidosis burden and differentiate ATTR-CM from other etiologies.
Ren et al. (2021) conducted an observational in Suspected ATTR cardiomyopathy (n=37). 99mTc-PYP quantitative SPECT vs. AL cardiac amyloidosis and other myocardial disorders was evaluated on Standardized uptake value (SUVmax) in myocardium (p=<0.05). 99mTc-PYP quantitative SPECT demonstrated significantly higher SUVmax in patients with ATTR cardiomyopathy (7.50 g/ml) compared to AL cardiac amyloidosis (1.96 g/ml) and other disorders (2.00 g/ml).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: